CABL Study: Circulating Tumour DNA (ctDNA) as a Biomarker of Response to Anti-Cancer Therapy in B-cell NH lymphoma
Non-Hodgkin Lymphoma (NHL) is a heterogeneous group of diseases with over 60 specific subtypes. While significant advances have been made in the sub-classification of NHL, methods of disease assessment have remained relatively unchanged. Additionally, although frontline treatment options are similar across subtypes of NHL, response can vary, necessitating close monitoring after therapy. In this study, serial plasma collections will be analysed for circulating tumour DNA (ctDNA) content with the aim of assessing this as an easily accessible surrogate of tumour burden. The performance of ctDNA will be compared to that of PET scanning to assess the relative usefulness of these two methods for NHL monitoring. A baseline, pre-treatment tumour sample (Fresh-frozen or FFPE index lesion) will also be collected and analysed using the Peter MacCallum PanHaem NGS panel at no cost to participants. The results will be returned in real-time to clinicians.
Other (specify below)
Can this be done remotely?
Parts of research done:
Literature review, Research proposal, Ethics approval
Addition of sites for study recruitment
Epworth Medical Foundation
Prospective researchers receive:
Dr Costas Yannakou